Welcome to our dedicated page for ClearPoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro director Timothy T. Richards exercised 12,417 restricted stock units into 12,417 shares of common stock. The RSUs were granted on May 22, 2025 and vested on their scheduled vesting date, converting into common shares at no cash exercise price.
Following this settlement of equity compensation, Richards directly owns 92,613 shares of ClearPoint Neuro common stock. The filing does not show any open-market purchases or sales, only the vesting and share issuance related to previously granted RSUs.
ClearPoint Neuro director Kristine B. Johnson exercised and settled 12,417 restricted stock units into an equal number of common shares on May 19, 2026. These RSUs were granted on May 22, 2025 and vested on their scheduled vesting date. After the settlement, she directly holds 71,116 shares of ClearPoint Neuro common stock.
ClearPoint Neuro director Pascal E. R. Girin settled a restricted stock unit award into common shares. On May 19, 2026, he exercised 12,417 restricted stock units, receiving 12,417 shares of ClearPoint Neuro, Inc. common stock at no cash exercise price. After this settlement, he directly holds 110,623 common shares. The RSUs were originally granted on May 22, 2025 and vested on their scheduled vesting date tied to the earlier of the first anniversary of grant or the day before the company’s 2026 annual meeting of stockholders.
ClearPoint Neuro director Linda M. Liau acquired 12,417 shares of common stock through settlement of restricted stock units. These RSUs were granted on May 22, 2025 and vested on their scheduled date, converting into the same number of common shares. After this compensation-related transaction, she holds 64,801 shares of ClearPoint Neuro common stock directly. No open-market buys or sells were reported in this filing.
CLPT reported a Form 144 notice to sell 16,000 shares of Common Stock. The shares are described as restricted stock vesting under a registered plan with a vesting date of 05/16/2025. The filing lists the transaction on NASDAQ and identifies the transaction type as compensation.
ClearPoint Neuro, Inc. disclosure: MAK Capital Fund LP, MAK Capital One LLC and Michael A. Kaufman report 1,901,489 shares of Common Stock beneficially owned, representing 6.3% of the class. The calculation is based on holdings as of 05/15/2026 and 29,989,563 shares outstanding as of May 7, 2026.
The filing identifies shared voting and dispositive power over the 1,901,489 shares and lists principal business addresses for the reporting persons.
ClearPoint Neuro, Inc. reports first-quarter 2026 results showing strong top-line growth but continued operating losses. Total revenue rose to $12.1 million from $8.5 million a year earlier, a 43% increase, driven by higher neurosurgery navigation, therapy, and capital equipment sales, including contributions from the IRRAflow and Prism platforms.
Biologics and drug delivery revenue was stable at $4.8 million, while neurosurgery navigation and therapy revenue jumped 80% to $5.9 million and capital equipment and software revenue rose 177% to $1.4 million. Gross margin improved to 64% from 60% as lower excess and obsolete inventory charges offset higher volumes.
Operating expenses grew sharply as the company invested in research, sales, and infrastructure following the IRRAS acquisition. Research and development costs increased to $4.5 million, sales and marketing to $6.7 million, and general and administrative to $5.0 million. Net loss widened to $9.6 million from $6.0 million, or $0.32 per share versus $0.22 per share. Cash, cash equivalents, and restricted cash totaled $36.5 million at quarter-end, and management believes current liquidity is sufficient for at least twelve months under its forecasts.
ClearPoint Neuro reported first-quarter 2026 revenue of $12.1 million, up 43% from $8.5 million a year earlier, driven by IRRAflow contributions and strong device demand. Organic revenue grew 16%, with organic devices up 25%, and gross margin improved to 64% from 60%.
Neurosurgery navigation, therapy and access revenue rose 80% to $5.9 million, while capital equipment and software revenue climbed 177% to $1.4 million. Operating expenses increased 44% to $16.2 million, reflecting the IRRAS acquisition and higher personnel and occupancy costs, resulting in a net loss of $9.6 million (–$0.32 per share).
The company ended March 31, 2026 with $35.6 million in cash and cash equivalents, down from $45.9 million at year-end, after using $8.0 million in cash for operating activities and $2.0 million for taxes on equity awards. ClearPoint issued a 2026 revenue outlook of $52.0–$56.0 million and highlighted integration of the IRRAflow portfolio, more than 60 active biopharma partners, new FDA clearance for the Velocity Alpha MR High Speed Surgical Drill System, a Health Canada license for its navigation system, and its first commercial drug delivery case in Asia-Pacific.